A Population‐adjusted Indirect Comparison of Cardiovascular Benefits of Once‐weekly Subcutaneous Semaglutide and Dulaglutide in the Treatment of Patients with Type 2 Diabetes, with or Without Established Cardiovascular Disease
Endocrinology Diabetes & Metabolism（2021）
关键词
cardiovascular risks,GLP-1 receptor agonist,type 2 diabetes
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要